# OnCo record lymphoma-tx-uk-access (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lymphoma-tx-uk-access/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lymphoma-tx-uk-access" ;
  schema:name "What the NHS in England funds for lymphoma, appraisal by appraisal"@en ;
  schema:alternateName "NICE lymphoma appraisals"@en, "Lymphoma drug funding England"@en, "Cancer Drugs Fund lymphoma"@en ;
  schema:description "A drug licensed for lymphoma is not automatically available on the NHS: NICE appraises each use separately and can recommend it, fund it for a while through the Cancer Drugs Fund, or refuse it. This entry lists what NICE decided for each lymphoma treatment, with the reference number to check."@en ;
  schema:url <https://onco.cc/terms/lymphoma-tx-uk-access/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:citation <https://www.nice.org.uk/guidance/ta874>, <https://www.nice.org.uk/guidance/ta872>, <https://www.nice.org.uk/guidance/ta1048>, <https://www.nice.org.uk/guidance/ta927>, <https://www.nice.org.uk/guidance/ta1113>, <https://www.nice.org.uk/guidance/ta954>, <https://www.nice.org.uk/guidance/ta892>, <https://www.nice.org.uk/guidance/ta894>, <https://www.nice.org.uk/guidance/ta883>, <https://www.nice.org.uk/guidance/ta1184>, <https://www.nice.org.uk/guidance/ta1001>, <https://www.nice.org.uk/guidance/ta524>, <https://www.nice.org.uk/guidance/ta577>, <https://www.nice.org.uk/guidance/ta754>, <https://www.nice.org.uk/guidance/ta720>, <https://www.nice.org.uk/guidance/ta1059>, <https://www.nice.org.uk/guidance/ta833>, <https://www.nice.org.uk/guidance/ta1081>, <https://www.nice.org.uk/guidance/ng52>, <https://www.nice.org.uk/guidance/ng47>, <https://www.nice.org.uk/guidance/ta1193> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/mechlorethamine/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/belinostat/>, <https://onco.cc/drugs/romidepsin/> ;
  onco:terms <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/> .